]>
IRCT20180603039959N5 IRCT 2025-02-15 Ahvaz University of Medical Sciences Thalidomide in Thalassemia Intermedia Investigating the Effects of Thalidomide on Hemoglobin Levels in Patients with Thalassemia Intermedia: A Clinical trial 2025-02-28 anticipated 50 Complete https://irct.ir/trial/81864 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment. 2 thalassemia intermedia. Intervention group:. No - There is not a plan to make this available Justification or reason for not sharing IPD is Due to concerns regarding patient privacy and ethical considerations, individual patient data (IPD) will not be shared. Additionally, data sharing may require legal permissions and compliance with data protection regulations.
public Daryush Purrahman
Golestan blvd
Ahvaz Iran (Islamic Republic of) 6135715794 +98 61 3375 0410 daryushpurrahman@gmail.com Ahvaz University of Medical Sciences scientific Daryush Purrahman
Golestan blvd
Ahvaz Iran (Islamic Republic of) 6135715794 +98 61 3375 0410 daryushpurrahman@gmail.com Ahvaz University of Medical Sciences Iran (Islamic Republic of) Visiting the Baghaei 2 Medical Center and having a medical record there Dependency on blood transfusions Lack of a favorable response to hydroxyurea treatment Age over 18 years Baseline hemoglobin level of less than 10 Signing the informed consent form 18 years no limit Both History of hypersensitivity reaction to thalidomide Pregnancy or breastfeeding D56.1 Beta thalassemia Treatment - Drugs Intervention group: Hemoglobin. Timepoint: Before starting the medication and at the end of 8 weeks. Method of measurement: Hemoglobin level will be measured using a complete blood count (CBC) test with a hematology analyzer. Ahvaz University of Medical Sciences Approved 2025-01-18 کارگروه/ کمیته‌ اخلاق در پژوهش دانشگاه علوم پزشکی جندی شاپور اهواز Farvardin Blvd, Golestan region Ahvaz Khouzestan Iran (Islamic Republic of)